ArticleEuropean journal of orthopaedic surgery & traumatology : orthopedie traumatologie2025
Comparison of histological response across patients with Ewing sarcoma treated with preoperative chemotherapy with or without preoperative radiotherapy.
Article in European journal of orthopaedic surgery & traumatology : orthopedie traumatologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Imaging of ewing sarcoma: an updated analysis including presenting features, prognostic imaging biomarkers, and treatment response assessment.Skeletal radiology · 2026Review
- A proposed radiological model for preoperative chemotherapy response prediction in patients with skeletal Ewing sarcoma.Skeletal radiology · 2026Article
- Comprehensive surgical and reconstructive management with in-depth complication analysis of giant pediatric sarcomas: a two-center tertiary experience.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2025Article
- Evaluation of Mithramycin in Combination with Chemotherapeutic Agents Against Ewing Sarcoma Cell Lines.Cancers · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to compare the histological response, a surrogate preoperative treatment efficacy marker, of patients treated with preoperative chemotherapy with or without preoperative radiotherapy. Moreover, local recurrence in both groups was investigated.
methodsSurgical specimens from 210 patients with Ewing sarcoma were assessed between 2003 and 2020 to evaluate their histological response to preoperative treatment; 181 patients received preoperative chemotherapy, while 29 received both preoperative chemotherapy and radiotherapy. The histological response rate in the surgical section was assessed based on tumour necrosis and reparative fibrous tissue.
resultsThe median histological response rates were 100% (interquartile range = 83-100%) for the preoperative chemotherapy and radiotherapy group and 90% (interquartile range = 60-100%) for the preoperative chemotherapy group (P = 0.004). Multivariate logistic regression analysis indicated that the administration of the preoperative radiotherapy (Odds ratio = 3.36 [95% confidence interval, CI 1.32-8.54]; P = 0.011) and small tumour volume (< 200 mL) were associated with the achievement of > 95% histological response (Odds ratio = 0.52 [95% CI 0.27-0.99]; P = 0.047). Local recurrence occurred in 9.9% (18/181) of patients who received preoperative chemotherapy and in 2.4% (1/29) of patients who received both preoperative chemotherapy and radiotherapy (P = 0.258).
conclusionPreoperative radiotherapy might enhance histological response, potentially reducing local recurrence. Therefore, it should be considered for patients with Ewing sarcoma who are at high risk of local recurrence or may have inadequate surgical margins.
Indexed as
Identifiers
40526143What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.